ClinicalTrials.gg
CompletedNCT07146360Updated Aug 28, 2025

Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction

A Phase 3 interventional study of Revelise (GENERIUM, Russia) and Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany) in Myocardial Infarction (MI), sponsored by AO GENERIUM. Completed at 22 sites in Russia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by AO GENERIUM · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 years 2 months after the study started (first participant enrolled May 2014, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 19 studies in Myocardial Infarction with a site in Russia — 7 open to participants now, 8 under way, 1 of them phase 3. Myocardial Infarction · Russia.

Enrollment
6th of 12
180 · median 161
Started
2014
the only one that year
Phase 3
4 of 19
none open now
Registered
15th of 19
by date
Lead sponsor
2 of 19
AO GENERIUM

Among the 19 studies in Myocardial Infarction with a site in Russia, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2014, is one of 4 in phase 3, and was the 15th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

7 of the 19 studies in Myocardial Infarction with a site in Russia are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myocardial Infarction with a site in Russia, or all of them as a file.
02

Study summary

Thi is is a multi-center, randomized, single-blind, parallel group clinical trial to evaluate the efficacy and safety of the intravenious thrombolysis with Revelise® (GENERIUM, Russia) in comparosin with the Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany) in patients with acute myocardial infarction (MI) with ST-segment elevation on the electrocardiogram (ECG). The thrombolisis was performed within the period of up to 6 hours and from 6 to 12 hours from the MI symptoms onset.

Read the detailed description

Revelise®, lyophilizate for solution for infusion, 50 mg, is the proposed biosimilar recombinant human tissue plasminogen activator developed by GENERIUM JSC (Russia).

All the patients with acute myocardial infurction, enrolled into the study, have been randomised to receive either biosimilar product or a reference produc. The stratification factor was the time from the MI symptoms onset: 1) within the 6 hours and 2) from 6 to 12 hours. Each patient was then followed-up for 3 months, including up to 14 days in an inpatient facility. Coronary angiography was to be performed within the first 24 hours after the administration of the study products, but not earlier than 3 hours after beginning of infusion in case of confirmed thrombolysis (onset of myocardial reperfusion) and immediately - in the absence of reperfusion according to ECG data (ST-segment reduction by less than 50% afterthe infusion start). The patients' condition will be assessed at the scheduled visits.

03

Conditions studied

  • Myocardial Infarction (MI)

Keywords

  • Acute Myocardial Infarction
  • Thrombosis
  • Recombinant tissue plasminogen activator
  • Acute Coronary Syndrome
  • Coronary Syndrome
  • Chronic heart failure
  • Activated partial thromboplastin time
  • New York Heart Association
  • Thrombolytic therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 80 years
  2. Acute myocardial infarction with ST-segment elevation on (point J) in 2 or more consecutive leads of more than 0.2 mV in men or more than 0.15 mV in women in leads V2-V3 or more than 0.1 mV in other leads after not more than 12 hours from pain onset (lasting at least 20 minutes) in chest (at the time of screening).
  3. Written of the patient for participation in the trial and conduction of coronary angiography.

Exclusion criteria

Exclusion Criteria:

1. Significant bleeding at present or during the previous 6 months, hemorrhagic diathesis.

4. Congenital-hereditary hemorrhagic coagulopathy (hemophilia, etc.) in medical history 5. Concomitant administration of oral anticoagulants, for example, warfarin ( > 1.3).

6. Surgery of the brain or spinal cord, neoplasms of the brain or spinal cord in past medical history, traumatic brain injury during the last 3 months.

7. Intracranial (including subarachnoid) hemorrhage currently or in past medical history.

8. Hemorrhagic stroke or stroke of unknown etiology in the anamnesis, suspected hemorrhagic stroke.

9. Ischemic stroke or during the last 6 months. 10. Severe (systolic blood pressure higher than 185 mmHg or diastolic blood pressure higher than 110 mmHg) uncontrolled hypertension.

11. Extensive surgery or significant trauma during the previous 3 weeks (including any injury combined with this acute myocardial infarction).

12. Long-term or traumatic cardiopulmonary resuscitation (>2 min), delivery during the previous 10 days; recently performed puncture of an incompressible blood vessel (for example, subclavian or jugular vein).

13. Bacterial endocarditis, pericarditis. 14. Known arterial aneurysms, defects in arteries or veins' development, suspected aortic dissection.

15. Confirmed gastric ulcer or duodenal ulcer during the last 3 months. 16. Known severe liver diseases, including liver failure, cirrhosis, portal hypertension (including esophageal varicose veins dilatation), active hepatitis.

17. Acute pancreatitis. 18. Known neoplasm with an increased risk of bleeding. 19. to the components of the product, allergic reactions to gentamicin in past medical history.

20. Pregnancy or lactation.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Revelise® (GENERIUM, Russia)

    аlteplase

    Biological: Revelise (GENERIUM, Russia)

  • Active comparator
    Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)

    аlteplase

    Biological: Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)

Interventions

  • BiologicalRevelise (GENERIUM, Russia)

    1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg. \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes. 2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg. * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg.

  • BiologicalActilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)

    Drug page: Tissue Plasminogen ActivatorStudies of Tissue Plasminogen ActivatorTissue Plasminogen Activator pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg. \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes. 2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg. * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg.

06

What researchers measure

Primary outcomes

  1. Myocardial reperfusion rate confirmed by the coronary angiography (CAG)

    Myocardial reperfusion confirmed by the CAG: coronary blood flow TIMI 3 or 2 degrees are considered to be myocardial reperfusion. Grade 3 - normal coronary perfusion: antegrade blood flow and contrast washout distal to the site of obstruction do not differ from those in an unaffected vessel; grade 2 - incomplete coronary perfusion: complete contrasting of the coronary artery distal to the site of obstruction, however, there is a delay in filling of the distal bed or slowdown in contrast washout).

    Time frame: In 3 hours after the beginning of IV thrombolysis in case of ECG data of successful reperfusion and immediately - if there is no effect of thrombolysis based on ECG data.

Secondary outcomes

  1. Frequency of percutaneous coronary intervention (PCI)

    Frequency of performing PCI after the intravenous thrombolysis results.

    Time frame: During the first day after the intravenous thrombolysis, but not earlier than 3 hours after the start of the infusion in case of coronary reperfusion and immediately in case of nocoronary thrombolysis based on ECG data

  2. Cardiovascular mortality

    Cardiovascular mortality in the period up to 30 days after acute myocardial infarction

    Time frame: Up to 30 days after acute myocardial infarction

  3. Myocardial reperfusion rate according to ECG data.

    Myocardial reperfusion rate according to ECG data - by ST-segment resolution (reduction) by 30%, 50%, 70% or more than 90 minutes after the beginning of the product administration in patients with acute myocardial infarction for up to 6 hours and by ST-segment resolution (reduction) by 50% or more than 180 minutes after the beginning of the product administration in patients with acute myocardial infarction during the period from 6 to 12 hours from the disease onset. (Resolution of ST segment elevation is calculated as follows: the amount (by leads) of ST segment elevation before therapy (at point J) minus the amount of ST segment elevation after therapy (90 or 180 minutes after the beginning of the product administration) divided by the amount of ST segment elevation before therapy and expressed as a percentage.)

    Time frame: 90 or 180 minutes after the beginning of the IV thrombolysis.

  4. Overall mortality

    Any cause mortality after acute myocardial infarction

    Time frame: Up to 90 days

  5. Incidence of post-infarction complications

    Incidence of post-infarction complications (true cardiogenic shock, clinical signs of congestive heart failure, acute left ventricular aneurysm, cardiac rupture, early post-infarction angina, recurrent myocardial infarction, brain infarction) during the first 30 days, except the rhythm disturbances

    Time frame: 30 days

  6. Incidence of the combined cardiovascular events

    Incidence of the combined cardiovascular events "death from cardiovascular diseases + recurrence of myocardial infarction + stroke" and "death from cardiovascular diseases + recurrence of myocardial infarction + stroke + heart failure" within 30 and 90 days after the acute myocardial infarction

    Time frame: Within 30 and 90 days

  7. Troponin changes

    Troponin concentration changes during the first 14 days after acute myocardial infarction

    Time frame: 14 days

  8. Fibrinogen concentration

    Concentration of fibrinogen in plazma sample

    Time frame: Days 1, 2 and 3

  9. D-dimer concentration

    Concentration of the D-dimer in plazma sample

    Time frame: Days 1, 2 and 3

07

Study locations

22 sites
  • Regional State Budgetary Healthcare Institution "Altai Regional Cardiological Dispensary"
    Barnaul, Altayskiy Kray 656055, Russia
  • City Budgetary Healthcare Institution of Arkhangelsk Region "First City Clinical Hospital named after E.E. Volosevich"
    Arkhangelsk, Arkhangelskaya oblast 163001, Russia
  • SBHI Republican Cardiology Center
    Ufa, Bashkortostan Republic 450106, Russia
  • State Budgetary Healthcare Institution of Novosibirsk "City Clinical Hospital No. 2"
    Novosibirsk, Novosibirsk Oblast 630051, Russia
  • Municipal Health Care Institution City Clinical Hospital No.4
    Perm, Perm Krai 614107, Russia
  • FSBEI of HVE Mordovia State University named after N.P. Ogarev, Medical Institute, SBHI MR "City Clinical Hospital No. 3"
    Saransk, Respublika Mordoviya 430005, Russia
  • Federal State Budgetary Scientific Institution "Scientific Research Institute for Complex Issues of Cardiovascular Diseases"
    Kemerovo, 650002, Russia
  • SBHI "State Budgetary Healthcare Institution of MHD"
    Moscow, 101000, Russia
  • Moscow City State Budgetary Healthcare Institution "Filatov City Clinical Hospital No. 15 of Moscow Healthcare Department"
    Moscow, 111539, Russia
  • State Budgetary Healthcare Institution of the city of Moscow "City Clinical Hospital No. 64 of Moscow Healthcare Department"
    Moscow, 117292, Russia
  • Federally Funded Higher Education Institution "Russian National Research Medical University named after N.I. Pirogov" of the Ministry of Health of the Russian Federation
    Moscow, 117997, Russia
  • Moscow City State Budgetary Healthcare Institution "Botkin City Clinical Hospital of Moscow Healthcare Department"
    Moscow, 125284, Russia
  • SBHI "CCH No. 81 MHD"
    Moscow, 127644, Russia
  • SBHI "Sklifosovsky Research Institute of Emergency Medicine of MHD"
    Moscow, 129090, Russia
  • Novosibirsk Region State Budgetary Healthcare Institution "City Clinical Hospital No. 1"
    Novosibirsk, 630047, Russia
  • Novosibirsk Region State Budgetary Healthcare Institution "City Clinical Hospital No. 34"
    Novosibirsk, 630054, Russia
  • Municipal Budgetary Healthcare Institution "City Emergency Medical Hospital of Rostov-on-Don"
    Rostov-on-Don, 344068, Russia
  • SI "St. Petersburg Dzhanelidze Research Institute of Emergency Medicine"
    Saint Petersburg, 192242, Russia
  • St. Petersburg State Budgetary Healthcare Institution "Pokrovskaya City Hospital"
    Saint Petersburg, 199106, Russia
  • FSI Saratov Research Institute of Cardiology of Russian medical Technologies
    Saratov, 410028, Russia
  • State Healthcare Institution "City Clinical Hospital No. 12"
    Saratov, 410039, Russia
  • SBHI SC "Stavropol Regional Clinical Hospital"
    Stavropol, 355000, Russia
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Nov 2017, 41 months.

Of 58 phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's 41 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Aug 28, 2025
StartActual
May 25, 2014
Primary completionActual
Nov 21, 2017
CompletionActual
Dec 11, 2017
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146360
Lead sponsor
AO GENERIUM
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
May 25, 2014
Primary completion
Nov 21, 2017
Completion
Dec 11, 2017
Last update
Aug 28, 2025

Study contacts

Oksana A. Markova, MD
study chair

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion